Forty-four nonreplicate clinical isolates of Pseudomonas aeruginosa that were resistant to extended-spectrum cephalosporins (ceftazidime and cefepime) and aztreonam, that putatively produced an acquired extended-spectrum ␤-lactamase (ESBL), according to the results of a double-disk synergy test, and that had been involved in nosocomial outbreaks were obtained from six different hospitals in northern Italy and screened for the presence of bla PER ESBL determinants. Twenty isolates, associated with nine independent outbreaks that occurred in five hospitals in the Milan area and its surroundings during 1995-2000, were found to carry an acquired bla PER-1 gene. PER-1 producers representative of the nine outbreaks exhibited a multidrug resistance (MDR) phenotype, including resistance to extended-spectrum cephalosporins, aztreonam, meropenem, aminoglycosides, and in most cases, imipenem and ciprofloxacin. An analysis of macrorestriction profiles of their genomic DNAs by pulsed-field gel electrophoresis revealed an overall clonal diversity of the PER-1 producers, although interhospital clonal spread was also observed. The bla PER-1 gene was not transferable and appeared to be chromosomally located. An analysis of the EcoRI and EcoRV restriction fragment length polymorphisms of the bla PER-1 locus revealed identical patterns for all isolates, and the characterization of a 1.9-kb region containing bla PER-1 revealed a conserved structure in representatives of the various clonal lineages. The present findings indicate that MDR P. aeruginosa clones producing the PER-1 ESBL are endemic to this area of northern Italy, where they have been circulating since the mid-1990s and have been associated with several nosocomial outbreaks.
spectrum ␤-lactam resistance (10) . However, acquired extended-spectrum ␤-lactamases (ESBLs) encoded by mobile genetic elements, such as serine-␤-lactamases of molecular classes A and D and metallo-␤-lactamases of molecular class B, are important emerging resistance mechanisms in P. aeruginosa (11, 15, 29) .
Among the acquired enzymes, PER-1 is a class A ESBL of notable clinical importance, due to its high level of activity toward oxyimino-cephalosporins and to the broad diffusion achieved by it in some epidemiological settings (16, 17, 20, 28) , for which a poorer outcome of infections caused by PER-1 producers has been reported (27) . In Italy, PER-1 was previously reported from two hospitals. At the Varese University hospital, sporadic isolates of PER-1-producing P. aeruginosa and Alcaligenes faecalis were detected (20; F. Luzzaro, G. M. Rossolini, M. Perilli, L. Pagani, R. Belloni, L. Lauretti, G. Amicosante, and A. Toniolo, Abstr. 99th Gen. Meet. Am. Soc. Microbiol., abstr. A-73, 1999), and a PER-1-producing P. aeruginosa clone recently caused a major outbreak in the general intensive care unit (ICU) (12) . At the Pavia University hospital, PER-1-producing isolates of Proteus mirabilis that are resistant to extended-spectrum cephalosporins have recently been detected in various wards (19) .
In this study, we report the detection of multidrug-resistant P. aeruginosa isolates producing the PER-1 ESBL that have been involved in nosocomial outbreaks in various hospitals in northern Italy since 1995. A molecular characterization of these isolates was performed to investigate their relationships and the spreading patterns of the bla PER-1 determinant.
MATERIALS AND METHODS
Clinical isolates. The P. aeruginosa strains analyzed in this study were nonreplicate (one per patient) clinical isolates from six different hospitals in Northern Italy (Fig. 1 ) that were isolated during the period 1995-2000. All isolates were resistant to oxyimino-cephalosporins (ceftazidime and cefepime) and aztreonam and putatively produced a secondary ESBL, according to the results of a doubledisk synergy test performed as described below. All isolates had been involved in nosocomial outbreaks, defined on the basis of epidemiological data (three or more nonreplicate nosocomial isolates that showed identical or similar resistance profiles and were spatially and temporally related according to clinical records). In some cases, a single representative per outbreak was obtained, while in other cases multiple isolates from the same outbreak were present. The identification of the isolates was always double-checked by using the GNI card of the Vitek System (BioMérieux, Rome, Italy).
Susceptibility testing. In vitro susceptibility was determined by a broth macrodilution procedure using cation-supplemented Mueller-Hinton (MH) broth (Difco Laboratories, Detroit, Mich.), as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (13) . The results of susceptibility testing were interpreted according to the criteria of the NCCLS (14) . Antimicrobial agents were purchased from Sigma Chemical Co. (St. Louis, Mo.) unless otherwise specified. Cefepime and aztreonam were purchased from BristolMyers Squibb (Wallingford, Conn.), imipenem was from Merck (Rome, Italy), meropenem was from Astra-Zeneca (Milan, Italy), piperacillin and piperacillintazobactam were from Wyeth (Catania, Italy), and ciprofloxacin was from Bayer (Milan, Italy). P. aeruginosa ATCC 27853 was used for quality control purposes in susceptibility testing. Susceptibility to tellurite was tested as described previously (7), using brain heart infusion agar (Oxoid Unipath, Milan, Italy) containing 0.5 mM K 2 TeO 3 (Sigma Chemical Co.). P. aeruginosa K3913/SI, a telluriteresistant strain from our collection, and P. aeruginosa PAO1 were used as a positive and negative control, respectively.
␤-Lactamase assays. The double-disk synergy test for the detection of ESBL activity was performed essentially as described previously (12) by screening for synergism between clavulanate (represented by a disk of amoxicillin-clavulanate) and ceftazidime, cefepime, or aztreonam. The disks were placed at a distance of 20 mm (center to center). A potentiation of the inhibitory zones of any of the expanded-spectrum ␤-lactams by clavulanate was considered suggestive of ESBL production. P. aeruginosa ATCC 27853 and P. aeruginosa 87SM (a clinical isolate from our collection that overproduces the AmpC enzyme) were used as negative controls. P. aeruginosa VA-463/98, which produces the PER-1 enzyme (12), was used as a positive control.
Analytical isoelectric focusing (IEF) of crude bacterial lysates for the detection of ␤-lactamases was carried out in polyacrylamide gels containing ampholines (pH range, 3.5 to 10), as described previously (18) . Crude extracts were prepared by sonication from early-stationary-phase cultures grown aerobically at 37°C in antibiotic-free brain heart infusion broth (Biokar Diagnostics, Milan, Italy). ␤-Lactamase bands were visualized with the chromogenic substrate nitrocefin (Oxoid Unipath) as described previously (18) . The activities of the ␤-lactamase bands separated by IEF against cefotaxime, ceftazidime, cefepime, and aztreonam were assayed by a substrate overlay procedure as described previously (18) .
Molecular analysis. Colony blot hybridization was performed as described previously (20) with bacteria grown directly on sterile nitrocellulose filters layered onto MH agar plates (Schleicher & Schuell, Dassel, Germany). P. aeruginosa VA-463/98 and P. aeruginosa ATCC 27853 were included as positive and negative hybridization controls, respectively. Southern blot hybridization was carried out on dried gels, as described previously (26) . Genomic DNA was extracted from P. aeruginosa as described previously (8) . Plasmid DNA extraction was done by the alkaline lysis method (23) , by the method of Kado and Liu (9) , and by the method of Hansen and Olsen (6) . The probe used for hybridization experiments was a PCR-generated amplicon comprising the entire bla PER-1 open reading frame (20) labeled with 32 P by the random priming technique by use of a commercial kit (Rediprime II DNA labeling system; Amersham, Milan, Italy). PCR amplification of the bla PER alleles was carried out with primers BLA-PER/F (5Ј-GGGACARTCSKATGAATGTCA) and BLA-PER/R (5Ј-GG YSGCTTAGATAGTGCTGAT), as described previously (20) . The sequenced region included the coding sequence for the mature PER-1 enzyme and the last 10 amino acids of the signal peptide. The region containing the bla PER-1 gene of isolate Ps101PAT was cloned from a genomic library constructed in the plasmid vector pBC-SK (Stratagene Inc., La Jolla, Calif.) by screening the library with the same bla PER-1 probe used for the hybridization assays (described above). The characterization of the region containing the bla PER-1 gene in other PER-1-positive clones was performed by a PCR mapping and sequencing approach. Primers PER-EXT1/F (5Ј-CC GGG GAA ATG CAG GCT GA) and PER-EXT1/R (5Ј-GAA TTC GCT CAT GCT GAA GAT TA), designed for the terminal regions of the cloned fragment, were used for the amplification reaction, and custom primers were used for amplicon sequencing. PCRs were always carried out with the Expand high-fidelity PCR system (Roche Molecular Biochemicals, Mannheim, Germany) and 10 ng of a genomic DNA template under the reaction conditions recommended by the manufacturer. Amplicon sequences were always determined for both strands, as described previously (20) .
Analysis of macrorestriction patterns of genomic DNAs by PFGE. Genomic DNAs for pulsed-field gel electrophoresis (PFGE) analysis were extracted from stationary-phase cultures grown in Luria broth (Sigma) by using a pathogen group reagent kit 3 (Genepath system; Bio-Rad, Richmond, Calif.). Digestion of the genomic DNAs was carried out with the enzyme SpeI, used as recommended by the enzyme manufacturer (Bio-Rad). PFGE was performed with 1% agarose gels in 0.5ϫ Tris-borate-EDTA buffer (23) at 14°C and 6 V/cm, using a Gene Path apparatus (Bio-Rad). After electrophoresis, the restriction fragments were stained with ethidium bromide and visualized under UV light. Comparisons of the PFGE patterns were interpreted according to the criteria of Tenover et al. (24) .
Gene transfer experiments. Conjugation experiments were performed on a solid medium (MH agar), with P. aeruginosa 10145/3 (an rpoB his derivative of the reference strain ATCC 10145 T ) used as a recipient. The initial donor/ recipient ratio was 0.1. Mating plates were incubated at 37°C for 8 h. Transconjugants were selected on MH agar containing ceftazidime (50 g/ml) plus rifampin (300 g/ml). The detection sensitivity of the assay was Ն5 ϫ 10 Ϫ8 transconjugants/recipient.
Nucleotide sequence accession number. The nucleotide sequence reported in this paper has been submitted to the EMBL and GenBank databases and assigned accession number AJ621265.
RESULTS
Detection of PER-1-producing P. aeruginosa isolates from different hospitals in northern Italy. A total of 44 nonreplicate clinical isolates of P. aeruginosa were investigated for the presence of acquired bla PER ESBL determinants. The isolates were collected from six different hospitals in northern Italy (Fig. 1) during the period 1995-2000 and fulfilled the following criteria: (i) resistance to oxyimino-cephalosporins (ceftazidime and cefepime) and aztreonam; (ii) putative ESBL production, as FIG. 1. Map of northern Italy showing the locations of the six hospitals from which the P. aeruginosa isolates investigated in this study were isolated. P.A.T., Pio Albergo Trivulzio Hospital; Nig., Niguarda Hospital; S.M., San Matteo Hospital. For each hospital, the total number of isolates and the number of PER-1-positive isolates are reported. The location of the hospital in Varese, from which PER-1-positive P. aeruginosa isolates were previously detected (12) , is also shown (shaded in gray).
indicated by a positive double-disk synergy test between clavulanate and at least one of the compounds mentioned above; and (iii) involvement in a nosocomial outbreak.
A colony blot hybridization assay using a bla PER-1 -specific probe yielded positive results for a total of 20 isolates from five different hospitals (Fig. 1 ). PCR analysis with primers designed for the amplification of known bla PER genes (20) yielded an amplification product of the expected size (966 bp) from each of the 20 hybridization-positive isolates (data not shown). Direct sequencing of the amplification products revealed, in all cases, the presence of a bla PER allele encoding a mature enzyme that was identical to PER-1 (16) . The putative ESBL producers that did not carry bla PER-1 -related sequences were not investigated further in this study.
A review of the epidemiological data for the 20 PER-1-positive isolates revealed that, overall, they had been involved in nine independent outbreaks in five different hospitals. A single representative of each outbreak (the earliest isolate available) was selected for further investigation ( Table 1) .
The susceptibilities to various antimicrobial agents of the nine PER-1-positive isolates that are representative of the nine outbreaks are reported in Table 1 . In addition to a uniform resistance to ceftazidime, cefepime, and aztreonam, all isolates were also resistant to meropenem, gentamicin, tobramycin, and netilmicin, and most of them were also resistant to ciprofloxacin and amikacin. More than half of the isolates retained susceptibility to piperacillin and piperacillin-tazobactam. In the double-disk test for ESBL detection, all of the PER-1 producers exhibited synergy between clavulanate and each extended-spectrum ␤-lactam (ceftazidime, cefepime, and aztreonam). None of the nine isolates grew in the presence of 0.5 mM tellurite.
Analytical IEF of crude extracts of the nine isolates, coupled with a bioassay to unravel the activities of the separated enzymes against oxyimino-cephalosporins and aztreonam, revealed in each isolate a ␤-lactamase with a pI of 5.3 that was active on cefotaxime, ceftazidime, cefepime, and aztreonam, consistent with the production of the PER-1 ESBL. An enzyme with an alkaline pI (range, 8.0 to 8.4) which did not show ESBL activity in the bioassay was also detectable in each isolate and most likely corresponded to the chromosomally encoded AmpC protein. Finally, an additional enzyme with a pI of 6.9 that exhibited ESBL activity was present in a single isolate ( Table  1 ). The nature of this enzyme was not investigated further in this work.
Clonal relationships of PER-1-producing isolates. The clonal relationships of the nine PER-1-producing isolates that were representative of the nine outbreaks were investigated by comparing the PFGE profiles of genomic DNAs after digestion with SpeI.
The PFGE profiles exhibited a notable degree of diversity. Only a couple of isolates (Pa34SM and Pa6NI) showed identical profiles (PFGE pattern A), and another couple (Pa105TR and Pa144TR) showed profiles that differed by only three bands (PFGE patterns F 0 and F 1 ). All other isolates exhibited profiles that differed from each other by more than four bands (Fig. 2) , so the nine PER-1 producers appeared to be distributed in seven different clonal lineages (Table 1) . It should be noted, however, that members of some clonal lineages differed Table 1] ). In some hospitals, multiple clones were present ( Fig. 1; Table 1) .
None of the PER-1 producers that were representative of the nine outbreaks was related to the isolate responsible for a nosocomial outbreak that previously occurred in the general ICU of the Varese Hospital (12), according to PFGE analysis (data not shown).
Transferability, genetic support, and environment of bla PER-1 gene. The transferability in conjugation experiments of the bla PER-1 determinant to a P. aeruginosa recipient was tested for each of the nine PER-1-positive isolates that were representative of the nine outbreaks. Conjugational transfer of the ESBL determinant was not detected in any case.
Plasmid DNAs were not detectable by agarose gel electrophoresis of either genomic or plasmid DNA preparations from any of the nine PER-1-positive isolates, even when plasmid DNAs were extracted by the method described by Hansen and Olsen (6) , which is suitable for detecting large Inc-P2 plasmids, some of the most common plasmids in P. aeruginosa (Fig. 3 , top panel; also data not shown). The absence of similar plasmids was also supported by the susceptibility to tellurite exhibited by all isolates (described above). For all of the isolates, Southern blot hybridization with a bla PER-1 probe yielded a hybridization signal corresponding to the band of chromosomal DNA (Fig. 3, bottom panel) , suggesting that the bla PER-1 determinant was inserted in the chromosome.
The restriction fragment length polymorphism of the bla PER-1 locus was investigated by Southern blotting using the bla PER-1 probe after the digestion of genomic DNAs with EcoRI or EcoRV (neither enzyme cuts inside bla PER-1 [16] ). With either enzyme, an apparently identical hybridization profile was observed for all isolates, consisting of a single band of approximately 4.2 kb after digestion with EcoRI and a single band of approximately 6.4 kb after digestion with EcoRV (Fig. 4) . A 1.9-kb SmaI-EcoRI genomic DNA fragment containing the bla PER-1 gene was cloned from isolate Ps101PAT (representative of clonal lineage E) into the plasmid vector pBC-SK. Sequencing of the cloned fragment revealed that the bla PER-1 gene from Ps101PAT was identical to that from P. aeruginosa RNL-1 (16) . The region downstream of bla PER-1 was virtually identical to that downstream of bla PER-1 in RNL-1 and was remarkably conserved compared to that downstream of bla PER-2 in plasmid pMVP-5 from Salmonella enterica serovar Typhimurium JMC (1) (Fig. 5) . The region upstream of bla PER-1 was identical to that upstream of bla PER-1 in RNL-1 for the first 27 bp but abruptly diverged beyond that point, while it exhibited a high degree of similarity for a longer tract with the sequence upstream of bla PER-2 (except for the presence of a 115-bp insertion in the latter) (Fig. 5 ). An open reading frame (truncated by the SmaI cloning site) is present in the region upstream of bla PER-1 (Fig. 5) , and it encodes a putative protein that exhibits 31% similarity with the transposase of an insertion sequence from a marine psychrotrophic bacterium (GenBank/EMBL database entry CAC84124) and less similarity with other (putative) transposases.
The structure of the region containing bla PER-1 was investigated, by a PCR mapping and sequencing approach, in representative isolates of the other clonal lineages. The results of these experiments revealed a structure identical to that of Ps101PAT for the bla PER-1 -containing regions of isolates Ps34SM (clonal lineage A), Pa40NI00 (clonal lineage B), Pa50SM (clonal lineage C), Pa66SM (clonal lineage D), and Pa105TR (clonal lineage F) (data not shown).
DISCUSSION
The antimicrobial susceptibility of P. aeruginosa has been reported to be on the decrease in several settings (4) . In Europe, a significant decline in susceptibility rates to ␤-lactams, quinolones, and aminoglycosides was recently observed for this species (4), and nosocomial outbreaks of multidrug-resistant P. aeruginosa, usually caused by clonal spread, have been described for various European hospitals (for examples, see references 2, 12, 22, and 25) . Although surveillance studies that establish baseline resistance patterns by geographic areas are numerous, the mechanisms underlying acquired antimicrobial resistance in P. aeruginosa isolates have been investigated in only a limited number of cases. A better knowledge of those mechanisms could be important for understanding the spreading patterns of resistant strains and of resistance determinants and for devising suitable control strategies.
For this study, we investigated the presence of PER-like ESBL determinants in isolates of P. aeruginosa that exhibited a resistance phenotype that was suggestive of ESBL production and that had been associated with nosocomial outbreaks in ), located in the same region, further supports the notion that PER-1-producing P. aeruginosa isolates have been endemic to this area for several years. In contrast, PER-1 producers were not detected at the Treviso hospital, which is located in a different region of northeastern Italy, suggesting that the resistance determinant may be absent or less widespread in that area. All of the PER-1 producers were not only resistant to extended-spectrum cephalosporins and monobactams, but also exhibited a multidrug-resistant phenotype that included most other antipseudomonal agents, leaving few therapeutic choices. Piperacillin-tazobactam was the most active among the tested drugs, although one-third of the strains were also resistant to this agent. PER-1 producers associated with epidemiologically independent outbreaks belonged to multiple clonal lineages, with different lineages usually being present in different hospitals. However, the presence of the same clone in different hospitals was also observed (PFGE type A, detected in two different hospitals, in Milan and Pavia), likely reflecting interhospital spread of the resistant clone caused by the transfer of patients or by subsequent admissions of patients to different hospitals in that area. The polyclonal nature of the PER-1-producing strains was similar to that observed in Turkey, where a remarkable endemicity of PER-1 producers has been reported for several hospitals (28) . The relatively broad distribution and polyclonal nature of PER-1-positive P. aeruginosa isolates detected in this area of northern Italy, along with the presence of the bla PER-1 determinant in strains of other species from the same area (19, 20) , indicate that the bla PER-1 determinant is also endemic to this region of northern Italy, where it may represent an important emerging resistance determinant in various gram-negative species.
In P. aeruginosa, the bla PER-1 gene has been found either in plasmids (3) or on the chromosome (28, 29) . In the isolates investigated in this study, the bla PER-1 determinants were apparently located on the chromosome, as suggested by the results of gene transfer, plasmid extraction, and hybridization experiments. An analysis of the bla PER-1 locus by Southern blotting and by PCR mapping and sequencing revealed a conserved structure in isolates from different clonal lineages, suggesting an overall conservation of the genetic element that delivered the resistance determinant to these strains. Interestingly, for our isolates the size of the EcoRI fragment recognized by the bla PER-1 probe was apparently the same as that found with most isolates from Turkey (28) . However, the region upstream of bla PER-1 was different from that in P. aeruginosa RNL-1 (16) , suggesting that a certain variability can also exist in the structure of the cognate genetic elements.
The fact that P. aeruginosa isolates producing the PER-1 enzyme tended to exhibit a multidrug-resistant phenotype that usually included aminoglycosides (12, 28; this study) could be related to a linkage between bla PER-1 and aminoglycoside resistance determinants within the same genetic element. We are currently investigating the structure of the element(s) carrying bla PER-1 . A preliminary characterization of bla PER-1 -flanking regions from these isolates revealed the presence of a gene for an original transposase that could pertain to the genetic element carrying bla PER-1 .
Finally, the results of this study also indicated that additional ESBLs are likely present in P. aeruginosa isolates that are resistant to extended-spectrum cephalosporins and aztreonam. Investigations of these enzymes are currently under way.
